Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 19/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2579247 | 0.96 | UTS2R (0.68) | UTS2R | |
| SCHEMBL2346361 | 0.92 | UTS2R (0.67) | UTS2R | |
| SCHEMBL2343963 | 0.90 | UTS2R (0.68) | UTS2R | |
| SCHEMBL2585279 | 0.89 | UTS2R (0.69) | UTS2R | |
| SCHEMBL14949832 | 0.89 | UTS2R (0.67) | UTS2R | |
| SCHEMBL14949862 | 0.87 | UTS2R (0.69) | UTS2R | |
| SCHEMBL2579621 | 0.87 | UTS2R (0.67) | UTS2R | |
| SCHEMBL2345909 | 0.86 | UTS2R (0.72) | UTS2R | |
| SCHEMBL2579249 | 0.86 | UTS2R (0.74) | UTS2R | |
| SCHEMBL3630715 | 0.85 | UTS2R (0.66) | UTS2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2161994-A2 | UROTENSIN II RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-03-17 | — | — | EP | claimed |
| US-20080318973-A1 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-12-25 | — | — | US | claimed |
| WO-2008153902-A2 | UROTENSIN II RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-12-18 | — | — | WO | claimed |
| US-8445514-B2 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-05-21 | — | — | US | disclosed |
| US-20110269768-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | KINNEY WILLIAM A | 2011-11-03 | — | — | US | disclosed |
| EP-2161994-A2 | UROTENSIN II RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-03-17 | — | — | EP | disclosed |
| US-20080318973-A1 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-12-25 | — | — | US | disclosed |
| WO-2008153902-A2 | UROTENSIN II RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269768-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | UTS2R, BDKRB2, AGTR2 | UTS2R 1/4885 |
| US-20080318973-A1 | Urotensin II receptor antagonists | UTS2R, BDKRB2, AGTR2 | UTS2R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.